ESEvgeniy V. Slepov

Evgeniy V. Slepov

*This is an algorithmically generated author record based on publicly available information.

Evgeniy V. Slepov has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Survivin protein as a predictor of disease course in non-muscle invasive bladder cancer

    by Denis V. Chernyaev, Черняев Денис Владимирович, N. S. Panamarev, Панамарев Н. С., E. V. Slepov, Слепов Е. В., L. A. Frank, Франк Л. А., R. A. Zukov, Зуков Р. А.

    Aim. To evaluate the diagnostic prospects of determining urine survivin level for monitoring the course of the disease in patients with non-muscle invasive bladder cancer (NMIBC). Materials and methods. In total, 66 urine samples from patients with NMIBC were analyzed. The survivin concentration in the urinary supernatant was determined by bioluminescent immunoassay. All patients with bladder cancer were examined and treated at the Krasnoyarsk Regional Clinical Oncological Dispensary named after A.I. Kryzhanovsky taking into account current clinical guidelines. The main clinical and morphological parameters were evaluated: histological variant of the tumor, invasion depth, differentiation grade, size and number of lesions in the bladder, and risk group for disease recurrence. As part of the follow-up, times to tumor recurrence, development of muscle-invasive cancer, and metastasis were determined. Statistical data processing was performed using Microsoft Excel software for Windows 10, StatTech v.4.11.2 (developed by Stattech LLC, Russia). Results. Urine survivin level of NMIBC patients before transurethral resection directly correlates with the risk group for disease recurrence. Decrease in the degree of tumor differentiation (p 0.001) and an increase in the size of the tumor (p = 0.021) increase concentration of the cancer marker. Survivin level of more than 10 pg/mL significantly reduces disease-free survival, and level of more than 50 pg/mL also reduces event-free survival and progression-free survival. Conclusion. The survivin cancer marker allows stratification of patients per unfavorable prognostic factors, which can be used to determine patient treatment tactics and subsequent follow-up.

  • Open Access

    Bladder Cancer Diagnosis and Monitoring Based on Urine Survivin (BIRC5) Bioluminescence-Based Immunoassay

    by Никита Сергеевич Панамарев, Денис Владимирович Черняев, Евгений Владимирович Слепов, Руслан Александрович Зуков, Людмила Алексеевна Франк

    Цель. Определить содержание сурвивина в моче пациентов с различными стадиями рака мочевого пузыря (РМП) разработанным биолюминесцентным иммуноанализом и оценить пригодность этого белка как маркера для диагностики и мониторинга течения РМП. Материалы и методы. В ходе исследования определено содержание сурвивина в 128 образцах мочи от больных РМП и 60 образцах здоровых добровольцев. Пациенты были обследованы с учетом современных клинических рекомендаций. Оценивали основные клинико-морфологические параметры: стадия, степень дифференцировки, размер и количество новообразований. Сурвивин в моче определяли биолюминесцентным иммуноанализом, разработанным ранее (диапазон определения — 15,6-1 000 пг/мл; предел обнаружения — 10,6 пг/мл). Взаимосвязь между клинико-морфологическими характеристиками опухоли и концентрацией сурвивина в моче пациентов оценивали при помощи критерия χ2 Пирсона. Результаты. Повышенное содержание сурвивина обнаружено у 79 больных, чувствительность и специфичность сурвивина как онкомаркера для диагностики РМП составили 61,7 % и 96,7 % соответственно. В группах с немышечно-инвазивным (Tа, Tis, Т1) и мышечно-инвазивным РМП (T2-4) чувствительность составила 51,9 % и 76,5 % соответственно. Выявлена взаимосвязь между концентрацией сурвивина в моче пациентов и патоморфологической стадией, размером опухоли, p < 0,05. Заключение. Содержание белка сурвивина в моче не может использоваться в качестве единственного диагностического фактора для выявления РМП. Для повышения чувствительности и специфичности лабораторного анализа на РМП целесообразно использовать несколько онкологических маркеров. Интерес представляет использование данного онкомаркера для мониторинга состояния больных, окончивших противоопухолевое лечение, а также в качестве преддиагностического показателя заболеваний мочеполовой системы. Разработанный способ выявления сурвивина в моче с помощью высокопроизводительного иммуноанализа на основе биолюминесцентного репортера обеспечивает быструю высокочувствительную детекцию этого маркера. Все компоненты аналитической системы (антитела, биолюминесцентная метка, субстрат реакции) разработаны в отечественных лабораториях, что делает анализ доступным.

  • Open Access

    Mutations of the PIK3CA gene in patients with breast cancer in the Krasnoyarsk region

    by A. V. Zyuzyukina, E. Yu. Yakunina, V. I. Borodulina, L. A. Vasilovskaya, E. V. Slepov, V. A. Komissarova, R. A. Zukov, Е. Ю. Якунина

    Aim. To identify population characteristics of the PIK3CA gene mutation among breast cancer patients in the Krasnoyarsk region.Materials and methods. The study included 140 patients with breast cancer with a certain mutation status of the PIK3CA gene, observed at the Krasnoyarsk Regional Clinical Oncology Center named after A.I. Kryzhanovsky. Determination of PIK3CA gene mutations (exons 2, 5, 8, 10 and 21) was carried out using commercial kits on equipment from Roche (Germany). Statistical processing of the obtained data was carried out using Microsoft Excel and Statistica 12 software products. The assessment of the factor of influence on the relapse-free and overall survival was carried out by constructing and comparing Kaplan–Meier curves. The result was considered statistically significant at a significance level of p 0.05.Results and conclusion. The overall frequency of occurrence of PIK3CA gene mutations is 38.6 %. The most common mutations are H1047X (55.4 %) in exon 21 and E545K (27.8 %) in exon 10. The median age of breast cancer patients with mutation status in the PIK3CA gene was 58.9 [49.0; 67.0] years, median time to relapse or progression was 62.2 [27.0; 84.0] months. There were no statistically significant differences in relapse-free survival between the presence and absence of mutations (p = 0.8). The effect of changes in PIK3CA on a decrease in overall survival rates (p = 0.047) in breast cancer patients was shown.

  • Role of maintaining therapy in the treatment of malignant neoplasms

    by R.A. Zukov, E.G. Astafieva, Yu.V. Batukhtina, E.V. Slepov

    The increase in the number and efficacy of antitumor therapy drugs is accompanied by the need for maintaining treatment. With an increase in the risk of adverse events, such as hepatotoxicity, hepatotropic drugs play a special role in the treatment of patients with malignant neoplasms. The presented clinical case demonstrates the efficiency of maintaining therapy with the drug Remaxol to reduce the frequency of adverse events when using brentuximab vedotin treatment regimens. Thus, the administration of remaxol at the initial stage of therapy can prevent the aggravation of clinical presentations and make it possible to continue the treatment using an effective antitumor regimen.


  • Open Access

    Possibility of modification of peripheral blood neutrophils functional activity during chemoradiotherapy in patients with anorectal cancer

    by E. V. Slepov, R. A. Zukov, M. S. Serbaeva, A. M. Karapetyan, O. V. Kashaeva, A. Yu. Pavlenko, Yu. V. Kozina

    Background. Ionizing radiation is an effective antitumor therapy, but it has a serious negative effect on the immune system requiring the use of radiation reaction prevention and reduction methods. Neutrophils are a sensitive element of the immune system both in interaction with tumor tissue and in response to radiation injury.Aim. To evaluate functional activity of peripheral blood neutrophils by chemiluminescent analysis in patients with anorectal cancer after radiotherapy.Materials and methods. The study included 80 patients with anorectal cancer. Patients received chemo- and radio-therapy with 3D conformal radiotherapy and radiation therapy under visual control, followed by the use of radioprotector and without it. Neutrophil activity determined by chemiluminescent analysis.Results. In patients with anorectal cancer found maximum spontaneous and induced chemiluminescence acceleration. The chemiluminescence activation index with luminol is lower in patients with anorectal cancer, and with lucigenin shows no differences with the control group. The low luminol chemiluminescence maximum intensity, as well as the decrease in the synthesis of reactive secondary oxygen species in enzymatic systems, is likely regulatory intracellular limitations consequence. After treatment, patients with radioprotector showed a decrease in the number of parameters with statistically significant differences with the control group. Undesirable phenomena associated with sodium deoxyribonucleate therapy not detected in anorectal cancer patients during radiotherapy and subsequent observation period.Conclusion. During treatment, differences in chemiluminescence parameters suggest that ionizing radiation affects them in patients with anorectal cancer receiving standard chemoradiotherapy. Use of chemoradiotherapy with a radioprotector leads to indirect restoration of cellular functional activity. This is confirmed by luminol-dependent chemiluminescence faster reaching its maximum and a decrease in the number of significant differences from the control group after the start of the drug treatment.

  • Open Access

    On the diagnostic and prognostic significance of the oncomarker survivin (BIRC5) in bladder cancer

    by Никита Панамарев, Евгения Башмакова, Александр Кудрявцев, Денис Черняев, Андрей Мазаев, Евгений Слепов, Руслан Зуков, Людмила Франк

    Цель исследования. Оценить содержание сурвивина в моче как диагностического маркера рака мочевого пузыря (РМП); изучить прогностическое значение полиморфизма -31G>C (rs9904341) в промоторной области гена BIRC5 в отношении агрессивности течения РМП среди населения Красноярского края. Материалы и методы. Иммуноанализом определен сурвивин в 43 образцах мочи пациентов: с РМП — 27, другим вариантом злокачественного новообразования — 4, воспалительными заболеваниями мочеполовой системы и доброкачественной гиперплазией — 8, здоровых — 4. Разработанным авторами способом на основе биолюминесцентного анализа генотипированы образцы ДНК 285 пациентов с РМП и 183 здоровых доноров. Количественные данные сравнивали U-тестом Манна-Уитни, критерием χ2 Пирсона — частоты генотипов среди случаев РМП и контролей. Ассоциацию между полиморфизмом и РМП оценивали по отношению шансов с 95 % доверительным интервалом, p < 0,05 считали значимым. Результаты. Установлено, что определение сурвивина в моче позволяет разделять пациентов с РМП и здоровых с чувствительностью 66,7 % и специфичностью 100 %. Повышенное содержание сурвивина обнаружено в образцах пациентов с воспалительными заболеваниями и доброкачественными гиперплазиями мочевыводящих путей. Показано, что полиморфизм -31G>C (rs9904341) для пациентов Красноярского края при оценке риска возникновения РМП и развития рецидива заболевания не является значимым. Носительство аллеля GG является возможным предиктором агрессивного течения заболевания с быстрым прорастанием в мышечную стенку мочевого пузыря (48,7 % vs 35,7 %, p = 0,02). Заключение. Сурвивин является хорошим преддиагностическим маркером для выявления пациентов с заболеваниями мочевых путей: его повышенный уровень в моче может указывать на развитие злокачественных (в т. ч. РМП) и доброкачественных гиперплазий, а также воспалительных заболеваний уротелия. Разработка отечественной «аларм» тест-системы по определению сурвивина в моче для быстрой и неинвазивной диагностики перспективна. Полиморфизм -31G>C (rs9904341) можно рассматривать как предиктор агрессивного течения РМП.


  • Open Access

    Sodium deoxyribonucleate effects on the status of cervical cancer patients after radiotherapy

    by Yu. V. Kozina, E. V. Slepov, O. V. Kashaeva, A. Yu. Pavlenko, R. A. Zukov

    Background. Apart from surgery and medications, radiation therapy is one of the main treatment methods for malignant tumors of the cervix. However, its use is associated with high incidence of urological complications. In addition, the need for long-term treatment, reduced level of patients’ quality of life promote the necessity to minimize the frequency of urological complications and justify search and study of the most adequate methods of their prevention.Aim. To evaluate the effect of radioprotector sodium deoxyribonucleate on clinical characteristics and quality of life of patients with cervical cancer after radiation treatment.Materials and methods. 80 patients with cervical cancer treated in A.I. Kryzhanovsky Krasnoyarsk Regional Clinical Oncology Dispensary. Patients received chemoand radiotherapy with the 3D conformal radiotherapy method in combination with intracavity gamma therapy sources of high dose with subsequent application of radioprotector and without it.Results. On the 3rd visit it was found that in patients with cervical cancer using a radioprotector, reduced red blood cells and flat epithelium cells content in the urine sediment, it may be due to the reparative and cytoprotective sodium deoxyribonucleate properties. In the assessment of the life quality after combined therapy completion with radioprotector, 60 % of patients’ responses to the health assessment questions of the last week differed from the comparison group. Undesirable phenomena associated with sodium deoxyribonucleate therapy not observed in cervical cancer patients during radiotherapy and subsequent observation period.Conclusion. Conformal external beam radiation therapy in combination with long-term intramuscular administration of a radioprotector has advantages compared to 3D conformal radiation therapy. This method reduces the severity of post-radiation side effects, increases time to development of hematological toxicity in the context of combination chemoradiotherapy, and reduces urothelial damage caused by chemoradiotherapy.

  • Open Access

    Phagocytic and chemiluminescent activity of blood neutrophils in patients with bladder cancer

    by Andrei A. Savchenko, Ruslan A. Zukov, Michael A. Firsov, Evgeniy V. Slepov, Vasiliy D. Belenyuk, I I Gvozdev, Alexander G. Borisov

    BACKGROUND: Tumor microenvironment modulates (including with the help of metabolites) the functional activity of the neutrophils that contribute to the reprogramming of the antitumor activity into a protumor one. AIMS: To study the phagocytic and chemiluminescent activity of neutrophils in patients with bladder cancer (BC) under the influence of metabolites of the tumor microenvironment in vitro. MATERIALS AND METHODS: We examined 37 patients with superficial BC (T1,а,isN0M0) and considered 32 healthy individuals as a control group. Neutrophils isolated from their blood were incubated in vitro with lactate, ADP, and glutamate. Phagocytic activity was examined using flow cytometry, and the intensity of the respiratory burst of neutrophils was evaluated via chemiluminescent analysis. RESULTS: In patients with BC, the phagocytic index (PhI) values are reduced compared to the control sample (without in vitro metabolite exposure) and when exposed to glutamate, while the effect of lactate on cells causes an increase in the phagocytic number and PhI. Moreover, under the influence of lactate in vitro, the activity of spontaneous and zymosan-induced chemiluminescence of neutrophils decreases. ADP causes a decrease in spontaneous chemiluminescence only. Finally, under the influence of glutamate, the indicators of spontaneous and induced chemiluminescence decrease. CONCLUSIONS: Under the influence of lactate and ADP (products of tumor cells), the phagocytic activity of a population of immature neutrophils is stimulated, which leads to myeloid suppressor cells that inhibit antitumor immunity. Thus, metabolites of the tumor microenvironment modulate the activity of the respiratory burst of neutrophils in patients with BC.

  • Open Access

    The evolution of modern notions about bladder cancer

    by Artem A. Yurchenko, Mikhail A. Firsov, Ruslan A. Zukov, Evgeny V. Slepov

    The review details the evolution in the researchers perspective of bladder cancer over the past five decades. The history of the study, pathogenesis, etiology, and the clinical significance of urinary bladder are briefly discussed. The review presents currently prominent theories regarding the pathogenesis of urinary bladder neoplasms and the foundational research in this field. The article briefly discusses the molecular changes the development of bladder cancer and studies of the urine microbiome during oncogenesis

  • Open Access

    Relationship of -31G/C (rs9904341) polymorphism in the survivin gene BIRC5 and the risk of bladder cancer

    by E. E. Bashmakova, N. S. Panamarev, A. N. Kudryavtsev, D. V. Chernyaev, E. V. Slepov, R. A. Zukov, L. A. Frank

    Purpose: To study the relationship between the -31G/C (rs9904341) polymorphism in the promoter region of the survivin protein gene and the predisposition to bladder cancer (BC) in patients of the Krasnoyarsk region. Material and methods. The allelic composition of the studied gene was determined in a group of 158 BC patients, consisting of 30 women and 128 men (mean age 65.6 ± 10.7, median: 66.5; C25–C75: 59–72). The control group included 117 healthy donors and consisted of 27 women and 90 men with an average age of 60.2 ± 5.1 (median: 60; C25–C75: 57–63.25). The allelic composition was determined using the bioluminescent method. A sample with the GC genotype confirmed by sanger sequencing (center for collective use “genomika”, Novosibirsk, Russia) was used as a control. The Mann–Whitney U test was used to compare quantitative data. the studied sample was in Hardy–Weinberg equilibrium (p>0.5). The pearson χ2 test was used to compare the frequencies of gene variants among BC cases and control samples. The association between variants rs9904341 and BC was assessed in terms of odds ratio (OR) with a 95 % confidence interval (CI); p valuesResults. The allelic composition was determined for the genes of patients and control group participants: GG – 62 (39.2%) vs 43 (36.8%); GC – 82 (51.9%) vs 54 (46.2%); CC – 14 (8.9%) vs 20 (17.15%). The relationship between the presence of the C allele and BC was assessed using the recessive inheritance model, combining all carriers – heterozygotes and homozygotes. The frequency of occurrence of genotypes for patients and the control group was established: GG + GC – 144 (91.1%) vs 97 (82.9%); CC – 14 (8.9%) vs 20 (17.1%). Thus, carriers of the CС genotype were significantly less in patients: OR (95% CI) 0.47 (0.23–0.98), p=0.04. The relationship with tumor invasion was not significant (p=0.08). Conclusion. Based on the results of detecting the rs9904341 (G/C) polymorphism among BC patients of the Krasnoyarsk region, a protective effect of the carriage of the CC genotype was found. In order to study the allelic composition with the threat of recurrence of the disease, additional research is needed.